Icotec Receives FDA Clearance for First-of-its-Kind BlackArmor® Implants to Treat Spinal Infections in the U.S

Icotec has become the first and only company in the United States to receive FDA 510(k) clearance for stabilising the spine in cases of de novo spinal infections.

These include discitis, osteomyelitis, pyogenic infection of the intervertebral disc, and other spondylopathies.

More than 15,000 patients in the United States require spinal stabilisation each year due to infections, highlighting the need for effective treatment options.

The clearance allows the use of BlackArmor® implants, which offer improved post-operative monitoring and visualisation.

In addition to this approval, the FDA has granted Breakthrough Device Designation (BDD) for the entire BlackArmor® spinal stabilisation portfolio.

This designation acknowledges the significant medical need and the potential benefits of BlackArmor® technology for patients with spinal infections.

Following the FDA's decision, the Centres for Medicare and Medicaid Services (CMS) has also approved BlackArmor® for New Technology Add-on Payment (NTAP).

This approval applies to innovative medical technologies that significantly improve the diagnosis or treatment of Medicare beneficiaries.

BlackArmor® implants, made from radiolucent Carbon/PEEK material, reduce imaging artefacts, improving post-operative monitoring and infection assessment.

Ongoing research continues to assess the effectiveness and safety of BlackArmor® implants in treating spinal infections.